London, UK, October 15th, 2026, FinanceWire

ARKBRIDGE, a multi-asset CFD trading platform, today announced its focus on the AI infrastructure investment framework developed by Senior Investment Specialist Jonathan Morelli.

The framework examines the semiconductors, memory, networking, data centres, cooling systems, electrical equipment and power infrastructure required to support the broader artificial intelligence economy, applying technology research, valuation analysis and portfolio-risk considerations to assess developments across the AI supply chain.

Morelli’s approach focuses on what he calls the “picks and shovels” of artificial intelligence: the semiconductors, memory, networking, data centres, cooling systems, electrical equipment and power infrastructure required by the broader AI economy.

Rather than attempting to predict which single AI company or model will ultimately dominate, Morelli studies the infrastructure that multiple competing AI businesses may need regardless of who emerges as the market leader.

“The AI winner five years from now may not be obvious today,” Morelli said. “But we already know that serious AI development requires computing capacity, memory, networking, data-centre infrastructure and power. My approach starts with what the entire industry cannot operate without.”

Within ARKBRIDGE.COM, Morelli has become a go-to Senior Investment Specialist for AI investment themes and the analytical tools used to evaluate them, combining technology-sector research with multi-asset analysis, valuation discipline and portfolio-risk considerations.

Jonathan Morelli’s AI Infrastructure Investment Framework

Morelli maps the AI economy as an interconnected investment chain:

Compute → Semiconductors → Memory → Networking → Data Centres → Cooling → Power

The framework is designed to identify areas where demand is increasing, capacity may be constrained and strategically important technologies are difficult to replace.

Morelli’s analysis begins with six questions:

• What infrastructure does the wider AI industry require?
• Where could demand grow faster than supply?
• Which suppliers serve multiple AI competitors?
• How difficult is the underlying technology to replace?
• How much future growth is already reflected in the valuation?
• How much AI-related exposure already exists within the portfolio?

For Morelli, the final question is particularly important.

An investor can hold several different AI-infrastructure companies and still carry significant concentration risk if all of those businesses depend on the same underlying capital-spending cycle.

“Different companies do not automatically mean different risks,” Morelli said. “Understanding where the opportunity sits is important, but understanding how much exposure the portfolio already has is just as important.”

ARKBRIDGE Multi-Asset Analysis Supports Morelli’s AI Research

Morelli’s framework fits within ARKBRIDGE’s broader multi-asset trading and analytical environment.

ARKBRIDGE currently provides access to 3,000+ global market instruments, allowing technology themes to be examined across equities, ETFs, indices, commodities, forex and other global markets.

That breadth matters because the AI infrastructure story extends beyond technology stocks.

Semiconductor demand can influence technology equities, while data-centre expansion can affect industrial companies, energy markets and infrastructure providers. Power constraints can influence utilities and commodities, while interest rates and currencies can affect the financing cost of major infrastructure projects.

Morelli therefore analyses AI as a broader economic ecosystem rather than as a single group of technology companies.

ARKBRIDGE Institutional Intelligence and Human Market Analysis

Morelli’s methodology also reflects ARKBRIDGE’s Institutional Intelligence approach.

The platform uses AI-supported analytics as a decision-support layer designed to help process market information, monitor volatility, compare sectors and identify relationships across asset classes.

For Morelli, technology helps surface changes in the market, while human analysis is still required to interpret why those changes matter.

Key questions include whether demand is temporary or structural, whether capacity is genuinely constrained, whether a supplier has pricing power and how much expected future growth is already reflected in the market price.

This combination of AI-supported analysis and experienced human interpretation is central to Morelli’s work within ARKBRIDGE.

Semiconductors, Data Centres and Power Remain Key Areas of Focus

Semiconductors form the first layer of Morelli’s research.

Advanced AI systems depend not only on processors but also on high-bandwidth memory, semiconductor fabrication, specialised manufacturing equipment, advanced packaging and networking.

Morelli looks for companies occupying strategically important positions deeper in that supply chain, particularly where multiple AI ecosystems depend on the same technology.

The same logic extends to data centres.

Modern AI facilities require servers, networking, cooling, electrical switchgear, transformers, grid connections and large quantities of reliable electricity.

Morelli therefore asks a simple question:

“If AI keeps growing, where must the money physically be spent?”

That question forms the foundation of his “picks and shovels” strategy.

Risk Management Remains Central to Morelli’s Approach

Identifying an attractive technology theme is only the first part of Morelli’s process.

The second is deciding how much risk the opportunity deserves.

Morelli considers position size, valuation, liquidity, volatility, leverage, correlation and existing technology exposure before focusing on potential return.

ARKBRIDGE supports this process with practical risk-management functionality including stop-loss orders, take-profit orders, trailing stops and margin monitoring, alongside AI-supported market analytics.

The tools are not intended to replace research. They support a process that begins with understanding the opportunity, identifying the risk and then determining how exposure should be structured.

ARKBRIDGE.COM Highlights Jonathan Morelli’s Specialist Role

ARKBRIDGE reports more than 50,000 clients and provides access to more than 3,000 global market instruments through its multi-asset trading environment.

Within that specialist-led model, Jonathan Morelli has developed a distinct focus on the infrastructure supporting artificial intelligence.

His research covers:

semiconductors, advanced memory, networking, data centres, cooling, electrical infrastructure and power.

For Morelli, the next important AI investment may not necessarily carry an “AI” label.

It may instead provide a component, technology or infrastructure service that several AI leaders cannot operate without.

“The most visible company is not always the company with the most valuable position in the supply chain,” Morelli said. “I want to understand what the AI economy cannot scale without.”

About Jonathan Morelli

Jonathan Morelli is a Senior Investment Specialist at ARKBRIDGE and one of the firm’s key specialists in AI-related investment research. His work focuses on the infrastructure supporting artificial intelligence, including semiconductors, memory, advanced packaging, networking, data centres, cooling, electrical systems and power infrastructure.

Morelli’s “picks and shovels” framework combines technology research, multi-asset analysis, valuation discipline and portfolio-risk considerations.

About ARKBRIDGE

ARKBRIDGE.COM is a multi-asset CFD trading platform that has operated since 2020 and reports more than 50,000 clients. The platform provides access to 3,000+ global market instruments and combines multi-asset execution, AI-supported analytics, risk-management functionality and account-security controls.

Official website: https://arkbridge.com/

ARKBRIDGE.COM provides execution-only services and does not provide personalised investment advice or discretionary portfolio management.

Risk Warning: CFDs are leveraged instruments and involve a substantial risk of loss. Investments linked to artificial intelligence, semiconductors and infrastructure can experience significant volatility. Market research, diversification and risk-management functionality cannot guarantee investment performance or eliminate market risk.

Contact

CMO
David Kaladze
davidk@arkbridge.com

Machine vision technology ensures 100% surface inspection and zero-blind-spot quality control for tablets and capsules.

Seoul, South Korea, 15th Oct 2026  – As pharmaceutical manufacturing processes become increasingly automated and production speeds rise, automated visual inspection (AVI) is becoming essential for ensuring the quality of tablets and capsules.

Visual inspection in pharmaceutical production goes beyond checking product appearance. During manufacturing, tablets and capsules can develop various defects, including chipping, cracks, foreign matter, discoloration, coating irregularities, and printing errors. Detecting these defects before shipment and selecting only compliant products is a vital step in pharmaceutical quality management.

Above all, this process is crucial for patient safety. Broken or chipped tablets and capsules with compromised contents do not represent acceptable product quality. Foreign matter or contamination poses severe hygiene and safety concerns, while cracked or peeling coatings can directly impact drug efficacy. For enteric-coated or sustained-release formulations designed to control the release site and rate of active ingredients, coating integrity is directly linked to product function. Defective coating may cause active ingredients to release too quickly or too slowly, affecting both safety and therapeutic outcomes. Therefore, visual inspection is a necessary quality assurance process to ensure patients receive medications that meet intended performance standards.

From a manufacturer’s perspective, consistent quality builds corporate and brand trust. Pharmaceutical companies exporting to international markets must stably meet quality standards across different regions. Defective products reaching the market can cause customer complaints, costly recalls, returns, and loss of business trust, making pre-shipment screening vital.

ENCLONY Co., Ltd., a specialist in automated pharmaceutical inspection systems, utilizes machine vision technology that captures and analyzes the entire surface of tablets and capsules from multiple angles. The system inspects top, bottom, and side surfaces of tablets, as well as the cylindrical body and ends of capsules, eliminating blind spots to identify defects such as chipping, contamination, discoloration, and coating or printing flaws.

Using algorithms that step-by-step learn normal product characteristics, ENCLONY sets inspection criteria tailored to each product. To prevent defect-identified items from mixing into compliant batches, the company applies a patented Triple Checking System. This technology re-verifies the removal of rejected items after sorting, ensuring defective products are reliably separated.

In terms of throughput, ENCLONY’s PLANET EV model can inspect up to 425,000 tablets per hour, while the high-speed PLANET EVS model processes up to 600,000 tablets per hour, enabling complete, 100% inspection even in high-volume production environments.

“For pharmaceutical companies, consistent quality is a key factor in building corporate trust, and for patients, it directly impacts receiving safe, reliable medications,” stated Kyung-Ho Lee, CEO of ENCLONY. “As production speeds increase, the importance of automated visual inspection technology that can evaluate every item against identical standards will continue to grow.”

Lee added, “ENCLONY plans to continuously advance its machine vision and automated inspection technologies to stably inspect full product surfaces and accurately sort defects, even in high-speed manufacturing environments.”

ENCLONY develops and supplies comprehensive automated inspection solutions for pharmaceutical manufacturing, including automated visual inspection systems for tablets and capsules, integrated laser printing and inspection systems, and containment inspection systems for high-potency active pharmaceutical ingredients (HPAPIs).

[About ENCLONY Co., Ltd.] ENCLONY Co., Ltd. is a South Korea-based technology leader specializing in automated visual inspection and laser printing systems for the pharmaceutical manufacturing industry.

For more information, please visit http://www.enclony.com

Media Contact

Organization: ENCLONY Co., Ltd.

Contact Person: Young-Mi Cho

Website: http://www.enclony.com

Email: Send Email

City: Seoul

Country: South Korea

Release id: 49942

View source version on King Newswire:
ENCLONY Expands Automated Visual Inspection Tech as Pharmaceutical Production Speeds Accelerate

Medspa Marketing Agency for USA has reported 200% growth in 2026, reflecting increased demand from medical spas seeking specialist support with their marketing and online visibility.

NEW YORK, NY — October 12, 2026 — Medspa Marketing Agency for USA has reported 200% growth in 2026, reflecting increased demand from medical spas seeking specialist support with their marketing and online visibility.

Based at 222 E 41st St, New York, NY 10017, the agency works with med spas across the United States. Its services help businesses present their treatments clearly online, reach prospective patients and create a more consistent path from initial enquiry to consultation.

The agency says its growth reflects the need for focused marketing in a competitive sector where prospective patients often compare providers, services and reviews before making contact.

“Medical spas need to make it easy for people to understand what they offer and take the next step,” said a spokesperson for Medspa Marketing Guys and Agency for USA. “We’re pleased to see more businesses looking for marketing support tailored to the needs of the med spa industry.”

Medspa Marketing Agency for USA supports medical spas with digital marketing designed around their services and business goals. The agency works with clients seeking to improve their visibility, communicate treatment information and generate enquiries from people interested in med spa services. Found at Medspa Marketing Agency for USA, 222 E 41st St, New York, NY 10017, United States, Phone: 07583 774098

The 200% growth reported in 2026 marks a significant year for the agency as it continues to serve med spas across the country. Businesses interested in learning more about its services can contact the agency directly.

About Medspa Marketing Agency for USA

Medspa Marketing Agency for USA provides marketing services for medical spas throughout the United States.

Media Contact

Organization: Med Spa Marketing Guys

Contact Person: Cormac Reynolds

Website: https://medspamarketingguys.com/

Email: Send Email

City: New York

State: New York

Country: United States

Release id: 49888

View source version on King Newswire:
Medspa Marketing Agency for USA Reports 200% Growth in 2026 and Opens in New York